The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Isomorphic Labs, the drug discovery start-up spun out of Google’s DeepMind artificial intelligence unit, has raised $600mn in its first external funding round, as investors bet on the potential for AI ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.

Isomorphic Labs is raising money in its first-ever external funding round from Thrive Capital, a big backer of ChatGPT ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...